Is microincisional surgery really the best option?

Article

The trend for microincisional procedures is escalating. Dr Boris Malyugin compares SICS and C-MICS.

Key Points

Because a MICS incision is smaller than the incision created by the conventional coaxial technique, one might expect improved outcomes, resulting in improved visual acuity. Previously published studies have established that the MICS technique is truly astigmatically neutral, making it ideal for refractive lens exchange; the technique is also associated with a decreased likelihood of postoperative wound leakage when compared with a larger incision procedure, thereby also reducing the risk of endophthalmitis.

B-MICS and C-MICS

That is why, nowadays, most surgeons prefer the coaxial surgical technique. My personal preference is a C-MICS procedure performed completely through an unenlarged 1.8 mm incision with the Stellaris system (Bausch & Lomb).

To evacuate the lens material through the smaller bore needle used in this technique, it is necessary to fragment the lens into particles of smaller diameter than is required by the standard diameter ultrasound (US) needle. Theoretically, with the larger diameter phaco needle, one could expect that, to emulsify the lens nucleus, a lower amount of US energy would be necessary.

Comparing C-MICS with SICS

Although there have previously been a number of studies assessing the outcomes of MICS, no studies have, to the best of my knowledge, compared the postoperative outcomes of 1.8 mm C-MICS with the outcomes of 2.8 mm SICS (small incision cataract surgery) when performed with the latest generation of phaco machines.

I conducted a study to assess if the differences in both the incision size and the US needle diameter - when using the same system and the same settings - influence either the utilization of the US energy and irrigating fluid or the clinical outcomes of cataract surgery.

Both groups underwent phacoemulsification using the same surgical settings:

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.